Previous 10 | Next 10 |
home / stock / nvo / nvo articles
The obesity market has garnered much interest lately, ever since Novo Nordisk (NYSE: NVO) received FDA approval for its obesity drug Wegovy in 2021...
Some 42% of adults in the United States are affected by obesity, according to the U.S. CDC. At a global level, a new study released by the journal ...
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage company focused on developing novel therapeutics for metabolic and endocrine disorders, has be...
Eli Lilly And Co (NYSE:LLY) has reportedly reached a settlement agreement with a medi spa that sold counterfeit versions of its popu...
Patients using Novo Nordisk’s (NYSE:NVO) (OTC:NONOF) obesity treatment, Wegovy, have reportedly maintained an average weight loss of 10% over...
Monday, Novo Nordisk A/S (NYSE:NVO) released headline results from the FRONTIER 2 Phase 3a trial of once-weekly and once-monthl...
Tesla and SpaceX CEO Elon Musk has sparked a conversation about childhood obesity and potential solutions after giving his...
Online pharmacies and slimming clinics in Britain are reducing prices for Novo Nordisk A/S’s (NYSE:NVO) Wegovy and&n...
Novo Nordisk A/S (NYSE:NVO) is witnessing a surge in the number of patients starting on its weight-loss drug, Wegovy, in the U.S. This increase com...
News, Short Squeeze, Breakout and More Instantly...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...
2024-07-13 17:52:00 ET Novo Nordisk (NYSE: NVO) is already a stock that's easy to justify buying. Between the incredible success of Ozempic, tons of demand for its weight loss medicine, and big investments in manufacturing as well as its pipeline, optimism about its future is practi...
2024-07-05 05:45:00 ET With Vertex Pharmaceuticals (NASDAQ: VRTX) announcing on June 21 that its therapy VX-880 helped nearly all of the patients with diabetes in a clinical trial to reduce or eliminate their need for other treatments, it's natural for investors to assume that Nov...